Heparin-binding EGF-like growth factor (HB-EGF) is a recently identified member of the EGF family of growth factors and a potent mitogen for smooth muscle cells and fibroblasts. 
amnity both EGF and HB-EGF. CHO mutant cells lacking heparan sulfate proteoglycans (HSPG) bind EGF equally well to wild-type cells and EGF binding is not affected by exogenous heparin. However, HSPG-defident EGF receptor-expressing cells do not bind si nt levels of HB-EGF unless heparin is present in the binding medium. Moreover, binding of radiolabeled EGF to HSPG-deficient EGF receptor-expressing cells is efficiently displaced by nonlabeled HB-EGF only in the presence of heparin. Signal transduction by the EGF receptor tyrosine kinase as evidenced by receptor autophosphorylation is induced by HB-EGF only in the presence of heparin, in contrast to EGF-induced receptor autophosphorylation, which is independent of heparin. These results directly demonstrate that HB-EGF but not EGF requires heparin or cell surface HSPG for binding and activation of the EGF receptor and that HB-EGF receptor interactions can be tightly regulated by the available local concentration of heparin-like molecules.
Heparin-binding EGF-like growth factor (HB-EGF) is a potent mitogen for smooth muscle cells and fibroblasts first identified as a secreted product of cultured human macrophages (1, 2) and is widespread in adult mammalian tissues (3) and wound fluids (4) . It is a member ofthe EGF family, which includes EGF, type a transforming growth factor, amphiregulin, vaccinia growth factor, the neu differentiation factor (5) , and the recently identified betacellulin (6) . They all share high sequence homology including six conserved cysteine residues, which are similarly spaced in the C-terminal part of the molecule (7) . HB-EGF is initially synthesized as a large precursor of 208 amino acids, which is eventually cleaved to yield the mature protein of at least 86 amino acids and a number of variants with N-terminal microheterogenicity. HB-EGF, as well as amphiregulin and neu differentiation factor has a 30-to 35-amino acid extension upstream from the EGF-like domain that is extremely hydrophilic due to the abundance of lysine and arginine residues (7). This cationic N-terminal extension is most probably responsible for the relatively high affinity of these growth factors for the glycosaminoglycan heparin.
A variety of growth factors have been characterized that form tight complexes with heparin and heparan sulfates (HS) including members of the fibroblast growth factor (FGF) family (8) , vascular endothelial growth factor (9), HB-EGF (2) , and the cytokines interleukin 3, granulocyte-macrophage colony-stimulating factor (10) , and interferon y (11) . Basic FGF (bFGF) was identified as a complex with HS proteoglycans (HSPG) on cell surfaces and basement membranes of diverse tissues and blood vessels (12, 13) . HSPG-bound bFGF is protected against heat inactivation and proteolytic degradation (14) . Recent studies identified an unusual role for heparin-like molecules in the formation of distinct bFGFheparin complexes that are essential for binding of bFGF to its cognate receptor (15) . The crucial role of cell surface HS was revealed by the finding that high-affinity receptor binding of bFGF was abolished in Chinese hamster ovary (CHO) mutant cell lines defective in their metabolism of glycosaminoglycans and receptor binding was restored upon addition of exogenous heparin (15) . Several studies have since shown that members of the FGF family require heparin for binding to their receptors and for biological activity (16) (17) (18) (19) (20) , and this interaction requires specific heparin structures (21) (22) (23) . As both EGF and HB-EGF seem to share the same high-affinity receptors (7), it is of great interest to determine the differential effects of heparin on the interactions of these growth factors with their receptor. (Amersham) by using the chloramine-T method (27) . The HB-EGF reaction mixture was loaded on a 0.2-ml heparin Sepharose column (Pharmacia) and eluted from the column with 1 ml of elution buffer (20 (Fig. 1A) . In contrast, HS-deficient cells expressing the EGF receptor show very little HB-EGF binding in the absence of heparin (Fig. 1A) . Binding of HB-EGF to these mutant cells was dramatically enhanced and fully restored when heparin was included in the binding medium. Heparin induces HB-EGF binding in a dose-dependent manner; furthermore, the binding curve plateaus, indicating saturation of the available HB-EGF binding sites (Fig. 1A) . Maximal receptor binding is achieved with heparin concentrations around 0.5 Mg/ml for purified HB-EGF and 0.1-0.2 Mg/ml for recombinant HB-EGF (data not shown). 1251-EGF, on the other hand, bound equally well to wild-type and HS-deficient cells expressing the EGF receptor with or without exogenous heparin (Fig.   1B ).
To unequivocally demonstrate that EGF and HB-EGF interact and with similar affinity with the EGF receptor and that heparin-dependent binding of HB-EGF did not result from any modification of the ligand during iodination (28), we tested the capacity of nonlabeled, recombinant EGF and HB-EGF to displace 1251-EGF on HSPG-deficient cells in the absence and presence of heparin (Fig. 2) 100 ng/ml and with a calculated apparent dissociation constant of 2-4 nM with or without heparin ( Fig. 2A) . HB-EGF, on the other hand, could not efficiently compete on the binding of 1251-EGF unless heparin was included in the binding medium (Fig. 2B ). In the presence of heparin (50 ng/ml), HB-EGF at 100 ng/ml completely blocked 125I-EGF binding and with an apparent dissociation constant of 1 nM. (Fig. 3) . These results are in complete agreement with the radioreceptor binding data shown in Fig. 1A expressed in HS-deficient cells in the absence and presence of heparin. Phosphorylated EGF receptor was immunoisolated using an anti-EGF receptor-specific antibody and visualized by immunoblotting with antibodies directed against phosphotyrosine. As shown in Fig. 4 , EGF receptor autophosphorylation is stimulated by EGF equally well in wildtype and HS-deficient cells with no additional effects of exogenous heparin. In contrast, without heparin HB-EGF does not stimulate the EGF receptor tyrosine kinase above basal phosphorylation level of the receptor detected in the absence of any added ligand. The addition of heparin, however, fully reconstitutes HB-EGF-induced EGF receptor autophosphorylation and tyrosine kinase activity in EGF receptor-expressing HSPG-deficient cells (Fig. 4) .
DISCUSSION
There is increasing evidence to support the hypothesis that binding of some FGFs to their high-affinity receptors is regulated by cell surface HSPG (15) (16) (17) (18) . Here, our results suggest that HB-EGF, which is apparently unrelated to the FGF family, also requires cell surface HSPG in order to bind and activate its high-affinity receptor. We present evidence that wild-type CHO Receptor immunoprecipitates were separated on an SDS/7.5% polyacrylamide gel, blotted onto nitrocellulose, and reacted with rabbit antibodies directed to phosphotyrosine.
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capacity to displace EGF from HSPG-deficient cells can be fully restored in a dose-dependent manner by including heparin in the binding medium. This is in marked contrast to the binding of EGF to the same receptor, which appears to be absolutely heparin independent. Moreover, signal transduction by the EGF receptor, as evidenced by receptor autophosphorylation, is stimulated by HB-EGF only in the presence of heparin or intact cell surface HSPG. These results directly demonstrate that HB-EGF but not EGF requires heparin or cell surface HSPG for binding and activating its high-affinity receptor. This may also help explain the recent observations that heparin potentiates HB-EGF-induced migration of smooth muscle cells (29) and mitogenesis in mouse epidermal keratinocytes (4) and is consistent with the findings that heparin-binding peptides derived from HB-EGF as well as heparinase pretreatment of cells modulate HB-EGF binding and biological activity (29, 30) .
Several models have been proposed to help explain heparin-dependent growth factor-receptor interactions. In the original model, it was suggested that interaction of bFGF with cell surface HSPG leads to a conformational change in the growth factor enabling the formation of an active bFGF, heparin, and FGF receptor trimolecular complex (15) . This induced fit model has recently been supported by direct physical measurements of infrared spectroscopy demonstrating an induced conformational change in bFGF after binding to heparin (31) . Our present study further contribute to the understanding of heparin-dependent growth factor-receptor interaction as it provides a demonstration of heparindependent and independent binding of two growth factors to one receptor.
It has been proposed that heparin-like molecules may induce the formation of active FGF dimers leading to FGF receptor dimerization and trans-activation (32) . Unlike FGF receptors, it is well established that dimerization of EGF receptors is an intrinsic property of the receptor molecules, which, although triggered by ligand binding, involves direct physical interaction of the two monomeric receptors (33, 34) . Moreover, oncogenic receptors in the EGF receptor family like the HER2/neu tyrosine kinase form homo-and heterodimers independent of ligand binding (35) . As EGF and HB-EGF differ mainly in their N-terminal region, which is responsible for heparin binding, it is somewhat unlikely that EGF receptor dimerization involves different molecular mechanisms for the two ligands. This implies that HB-EGFinduced receptor dimerization is most probably not a function of heparin-mediated ligand dimerization.
In a recent study, Kan and colleagues (36) have demonstrated that heparin can interact independently of the FGF ligand with a specific sequence in the extracellular domain of the FGF receptor and that this interaction is essential for binding of FGF to the receptor. Both EGF and HB-EGF share a common receptor that binds EGF regardless of cell surface HSPG but fails to bind HB-EGF unless HSPG or heparin is present. This effect of heparin on HB-EGF but not on EGF binding suggests that heparin most likely regulates ligand-EGF receptor interaction via binding to the ligand and not to the receptor. Nevertheless, one cannot exclude the possibility that cell surface HSPG could selectively determine the receptor's capacity to bind heparin-binding ligands such as HB-EGF, amphiregulin, and neu differentiation factor and not be involved in the binding of non-heparinbinding ligands such as EGF and type a transforming growth factor. It is, therefore, of great interest to determine whether EGF receptors possess an intrinsic heparin-binding site in their extracellular domain similar to that proposed for FGF receptors (36) .
While binding ofHB-EGF to the EGF receptor is enhanced at relatively low levels of heparin, higher heparin concentrations lead to inhibition of receptor binding similar to that observed with FGF. In a recent study analyzing the capacity of HB-EGF to compete for binding of 1251-EGF to A-431 cells, apart from the stimulatory effects of heparin, the major effect followed was a potent inhibitory activity of heparin on the capacity of HB-EGF to compete on 125I-EGF receptor binding (30) . The molecular mechanism underlying this biphasic effect of heparin on heparin-binding growth factors is not known. However, we have recently demonstrated that several cell surface-derived HSPG can inhibit bFGF receptor binding by direct competition with heparin (22) , and several recent reports have identified specific heparin structures that bind bFGF with various affinities (37, 38) . We hypothesized that both stimulatory and inhibitory types of HS exist that either promote or restrict bFGF receptor binding (22) . The balance between these two classes of HS may well contribute to the biphasic effects observed as well as determine the degree and extent of HB-EGF-induced cellular responses.
Ligand binding to receptor tyrosine kinases is followed by receptor dimerization, stimulation of protein tyrosine kinase activity, and autophosphorylation (33) . Here we show that not only HB-EGF binding but all subsequent steps in signal transduction leading to receptor autophosphorylation are heparin dependent. The lack of any enhancement of EGF receptor autophosphorylation by HB-EGF above background in the absence of exogenous heparin strengthens the notion that heparin-like molecules may be an absolute requirement for HB-EGF receptor interaction. Heparindependent activation and attenuation of HB-EGF receptor interactions may be expected to have marked physiological implications. For example, the action of HB-EGF secreted by macrophages in wound healing and arteriosclerotic lesions could be dramatically potentiated by local cellular-and tissue-specific HSPG. The differential capacity of heparin and HS to promote receptor binding of HB-EGF but not EGF could have spatial functional significance in determining the more diffuse, widespread action of EGF on the one hand and a highly restricted local activity of HB-EGF on the other. As such, the local concentration and activation of HB-EGF but not EGF by HSPG may well explain the observation that HB-EGF is by far a more potent mitogen and migration factor for vascular smooth muscle cells than EGF (29) .
